ABBV vs CRM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Salesforce, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Salesforce, Inc. · Technology
$182.14
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
CRM trades at a lower forward P/E
(22.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CRM |
| Current Price |
$197.69 |
$182.14 |
| Fair Value Estimate |
$210.22 |
$264.10 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$173.0B |
| Forward P/E |
83.3x
|
22.8x
|
| EV / EBITDA |
23.4x
|
14.4x
|
| Price / Sales |
5.7x
|
4.2x
|
| Price / FCF |
18.7x
|
12.0x
|
| Revenue Growth YoY |
+10.0%
|
+12.1%
|
| Gross Margin |
70.2%
|
77.7%
|
| Operating Margin |
26.7%
|
21.5%
|
| Return on Equity |
-361.6%
|
12.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
8.33%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Salesforce, Inc. is a leading enterprise software company specializing in cloud-based customer relationship management and enterprise applications. The company benefits from a durable competitive moat anchored by pioneering SaaS delivery, a large and growing customer base, and a diversified revenue mix with Service Cloud as the largest segment generating $9.05 billion in FY2025. Salesforce exhibi…
Accumulation Zones
| Metric |
ABBV |
CRM |
| Zone Low |
$157.66 |
$198.08 |
| Zone High |
$178.69 |
$224.49 |
| In Buy Zone? |
No
|
Yes
|